Dyax and ZymoGenetics Enter Into Library License Agreement for Discovery of Therapeutic Antibodies

03-Nov-2006

Dyax Corp. announced that it has granted a non-exclusive license to its proprietary antibody phage display libraries to ZymoGenetics, Inc. for the discovery of therapeutic antibodies. This collaboration with ZymoGenetics is part of Dyax's Licensing and Funded Research Program (LFRP) partnered with Paul Royalty Fund.

Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, clinical milestone payments, and royalties on net sales of products that may result from ZymoGenetics's use of the Dyax libraries. The agreement provides ZymoGenetics a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's antibody phage display technology.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous